The ADDF Highlights Encouraging Progress Toward Targeting Multiple Alzheimer’s Pathologies in Biogen’s Phase 2 Tau Study

B Findings point to continued momentum toward combination therapies that target the full pathobiology of the disease NEW YORK, May 14, 2026 /PRNewswire/ — Today, Biogen…
posteditor
posteditor
Articles: 21727

Other News